5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound studied as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not an FDA-approved drug and its use in humans is not supported by published controlled clinical trials as of July 2026.
Among longevity- and wellness-focused practices, 5-Amino-1MQ appears in provider inquiries alongside NAD+ and other metabolism-related compounds. Based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026, it ranks as the #9 most-requested product in this catalog. That ranking reflects interest, not endorsement: 5-Amino-1MQ sits in a heightened-caution regulatory tier, and the sections below lay out the open questions a prescriber should resolve before considering it.
What 5-Amino-1MQ Is
5-Amino-1MQ is a synthetic small molecule, not a peptide. Structurally it resembles nicotinamide, which allows it to occupy the substrate-binding pocket of NNMT while resisting the methylation reaction the enzyme normally carries out. In preclinical models, this competitive inhibition has been described as reducing NNMT activity.
NNMT methylates nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, a reaction that intersects one-carbon metabolism and the salvage pathways that regenerate NAD+. Researchers have investigated NNMT inhibition as a way to alter these pathways in adipose and other metabolically active tissue. This is the mechanistic context in which 5-Amino-1MQ is discussed. It is a laboratory research tool: the bulk of the published literature describes cell-culture and rodent experiments, and there is no established body of human safety or efficacy data. Providers should treat any mechanistic description as a hypothesis under study rather than a validated clinical effect.
How Providers Use It in Practice
Interest in 5-Amino-1MQ concentrates among longevity, metabolic, and wellness practices that already work with NAD+ and related compounds. Because the compound is not FDA-approved and has no approved indication, there is no labeled or on-label use to describe. Any clinical application is investigational and off-label by definition.
Some providers evaluate 5-Amino-1MQ in the context of metabolic and aging-related research rather than as an established therapy. Given the absence of human trial data, a prescriber considering it carries the full weight of the individualized clinical-need determination, informed-consent discussion, and documentation. This is not a compound with a settled place in practice; it is one where the evidence base and the regulatory footing are both unsettled, and the article's remaining sections are written to help providers weigh exactly that.
Forms and Combinations Available Through Compounding
Where compounding is contemplated for 5-Amino-1MQ, it has been discussed in oral (capsule) and injectable forms. Compounding, in principle, exists to prepare a medication tailored to a specific patient's documented needs when an FDA-approved product does not meet them. For 5-Amino-1MQ, that framing runs into a threshold problem: there is no FDA-approved 5-Amino-1MQ product of any kind, and the compound's eligibility for compounding itself is unresolved (see the regulatory section below).
We are not publishing dosage forms, strengths, or combination formats as recommendations. The practical point for providers is narrower: before form or format is even a question, the more fundamental question is whether a bulk substance may lawfully be compounded at all. For 5-Amino-1MQ, that question does not have a clear affirmative answer as of July 2026.
Regulatory Status and Provider Considerations
This is the section that should drive a provider's decision. As of July 2026:
- Not FDA-approved. 5-Amino-1MQ has no FDA-approved indication, no approved finished-drug product, and no USP monograph. It is a research chemical.
- Not on the 503A bulk drug substances list. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk substance may generally be used in compounding only if it is the subject of a USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. 5-Amino-1MQ meets none of these criteria.
- Not among the April 2026 Category 2 removals. In April 2026, FDA removed a defined set of substances from its interim "Category 2" bulk-substances list (substances that had been flagged as raising significant safety risks), routing them to Pharmacy Compounding Advisory Committee (PCAC) review. That action covered a specific group of peptides — including BPC-157, TB-500, and others — with PCAC review beginning July 2026. 5-Amino-1MQ was not part of that action. It is a distinct small molecule and was not on the removal list.
- Removal from Category 2 would not equal approval anyway. For the substances that were moved, FDA and multiple pharmacist commentators have stressed that removal from Category 2 does not authorize compounding; a PCAC review and a subsequent FDA determination would still be required. That caveat applies with even more force to 5-Amino-1MQ, which was never part of that reclassification.
- Enforcement posture. FDA has issued warning letters to sellers marketing unapproved research compounds for human use. Marketing an unapproved new drug, or compounding a substance that lacks a lawful basis for compounding, carries regulatory exposure.
Compounded medications are not FDA-approved and are not evaluated by FDA for safety, efficacy, or quality before dispensing. For 5-Amino-1MQ specifically, the compound also lacks the human evidence base that underpins many other compounded preparations. A provider weighing it should document the clinical rationale, confirm the legal basis for compounding with the dispensing pharmacy, and account for the limited safety data in the informed-consent conversation. When the lawful basis for compounding a bulk substance cannot be established, the conservative course is to not proceed.
Sourcing and Quality: What to Ask a Compounding Pharmacy
If a licensed pharmacy is consulted about any compounded preparation, these are standard diligence questions. For a research compound like 5-Amino-1MQ, the first question is threshold, not quality:
- Legal basis to compound. On what basis does the pharmacy conclude the bulk substance may lawfully be compounded (monograph, component of an approved drug, or bulks-list status)? For 5-Amino-1MQ, ask the pharmacy to identify that basis explicitly.
- API source and Certificate of Analysis (CoA). Where is the active ingredient sourced, and is a CoA available documenting identity and purity?
- USP compliance. Does the facility follow USP <795> (non-sterile), <797> (sterile), and <800> (hazardous drugs) as applicable to the dosage form?
- Potency and sterility testing. Are finished preparations tested for potency, and — for injectables — for sterility and endotoxin?
- Beyond-use dating. How is BUD assigned and substantiated?
- State licensure. Is the pharmacy licensed in the patient's state, and what is its inspection history?
If a pharmacy cannot articulate a lawful basis for compounding the substance, that answer is itself decisive.
Frequently Asked Questions
Is 5-Amino-1MQ FDA-approved?
No. As of July 2026, 5-Amino-1MQ has no FDA-approved indication, no approved finished product, and no USP monograph. It is a research compound, and any human use is investigational.
Was 5-Amino-1MQ affected by the April 2026 FDA peptide reclassification?
No. The April 2026 Category 2 removals covered a specific list of peptides scheduled for PCAC review beginning July 2026. 5-Amino-1MQ is a small molecule and was not part of that action, so its regulatory status was not changed by it.
Can a compounding pharmacy legally prepare 5-Amino-1MQ?
That question does not have a clear affirmative answer. 5-Amino-1MQ is not on the 503A bulk drug substances list, has no USP monograph, and is not a component of an FDA-approved drug — the usual pathways that permit a bulk substance to be compounded. A provider should ask the pharmacy to identify the specific legal basis before proceeding.
What does the human evidence look like?
Published research is predominantly preclinical — cell-culture and rodent studies of NNMT inhibition. There is no established body of controlled human clinical-trial data on safety or efficacy as of July 2026, which is a central consideration in any risk-benefit discussion.
Related Reading
- See where 5-Amino-1MQ ranks among the most-prescribed compounded medications
- Compounded NAD+: a provider overview
- Compounded glutathione and sterile-compounding quality
Clinics order compounded medications through platforms like ScriptLinkRx, which connect licensed providers with licensed compounding pharmacies.
Sources
- U.S. Food & Drug Administration, Human Drug Compounding
- U.S. Food & Drug Administration, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act
- U.S. Food & Drug Administration, Compounding and the FDA: Questions and Answers
- Roberti A, Fernández AF, Fraga MF. "Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation," National Library of Medicine (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC8372200/
